Psychedex is in open beta. We are still fine-tuning the generation and review process. Please double-check sources.
+1 more
25x-NBOMeLSD, psilocybin, mescaline +2 moreLSD, psilocybin, mescaline, 2C-x compounds, other NBOMe compounds show less
25N-NBOMe
4-nitro-2,5-dimethoxy-N-(2-methoxybenzyl)phenethylamine
25N-NBOMe is a synthetic psychedelic of the phenethylamine class. It is the nitro-substituted member of the NBOMe series, derived from Shulgin's 2C-N. 25N-NBOMe is a full agonist at 5-HT₂A receptors, producing its effects by powerfully activating serotonin-driven perceptual processing.[1]
Psychedex is in open beta. We are still fine-tuning the generation and review process. Please double-check sources.
+1 more
25x-NBOMeLSD, psilocybin, mescaline +2 moreLSD, psilocybin, mescaline, 2C-x compounds, other NBOMe compounds show less
Ralf Heim developed the compound in 2003 as a brain-imaging research tool, not for recreation.[2] It reached drug markets around 2010, routinely sold on blotter paper as LSD — the NBOMe series produced over 50 severe intoxication cases and at least 9 deaths.[3][2] 25N-NBOMe remains one of the least-distributed analogs, controlled in most countries under blanket psychoactive substance laws.
Subjective effects include geometric visual patterns, time alteration, physical stimulation, and anxiety. The experience has a pronounced anxious edge — harsher and more visually overwhelming than classical psychedelics, with a steep intensity curve where small dose changes can shift a trip from manageable to frightening. Thought loops, paranoia, and sensory overload are common unwanted effects.
25N-NBOMe produces no physical dependence, but the NBOMe class carries severe acute toxicity — seizures, organ failure, and cardiovascular collapse have caused multiple deaths.[4] The dose-response curve is steep, compressing the margin between a manageable dose and a medical emergency into an unpredictable sliver. No clinical studies exist on this compound; understanding rests on class pharmacology, lab data, and community reports.
History[edit]
Discovery
2C-N, the parent compound, was synthesized and self-tested by Alexander Shulgin and documented in PiHKAL (1991).[5] In 2003, Ralf Heim's doctoral thesis added an N-(2-methoxybenzyl) group to 2C compounds, dramatically increasing their affinity for serotonin receptors — designed for brain-imaging research.[2] This structural addition made the NBOMe series active at microgram doses.
Designer drug emergence
The NBOMe series reached online drug markets around 2010, sold on blotter paper and frequently misrepresented as LSD.[2] 25I-NBOMe, 25B-NBOMe, and 25C-NBOMe dominated distribution; 25N-NBOMe circulated in smaller volumes. More than 50 severe intoxication cases and at least 9 deaths accumulated across the series.[3][2]
Prohibition
Russia controlled the series in 2011, Sweden in 2013, and the United States permanently scheduled 25I-, 25C-, and 25B-NBOMe in October 2016.[6] 25N-NBOMe was not individually named but is likely covered by the Federal Analogue Act. Brazil explicitly listed 25N-NBOMe in 2014, and the UK's Psychoactive Substances Act 2016 provides blanket coverage.[7]
The name "NBOMe" comes from the compound's defining structural feature: the N-2-methoxybenzyl group. Within drug culture, NBOMe compounds are called "N-bombs" — a name that acquired darker meaning as fatality reports accumulated. The series carries a strongly negative reputation among psychedelic users; "NBOMe" became shorthand for the dangers of unregulated psychedelic markets.
Chemistry[edit]
Structural class
25N-NBOMe belongs to the 25X-NBOMe series of substituted phenethylamines. The class shares a phenethylamine backbone with methoxy groups at the 2- and 5-positions and an N-(2-methoxybenzyl) group — the structural addition that converts low-potency 2C compounds into potent serotonin-receptor agonists.[3] The parent compound is 2C-N.[5]
Molecular identity
The 4-nitro group (–NO₂) at position 4 is unique within the NBOMe series — every other member carries a halogen, methyl, or ethyl group at that position.[8] This group affects how the body breaks the molecule down: enzymes reduce it to a primary aromatic amine, giving 25N-NBOMe distinctive metabolic behavior. The molecular formula is C₁₈H₂₂N₂O₅ (346.4 g/mol).
Pharmacology[edit]
Mechanism of action
25N-NBOMe produces its psychedelic effects by fully activating serotonin receptors.[3] Unlike the parent 2C compounds, which activate them only partially, full agonism means stronger downstream signaling at the same level of receptor occupancy.[1] In animal models, blocking this single receptor type completely eliminates the behavioral effects, confirming it as the essential driver.[9]
The compound's high potency comes from the N-2-methoxybenzyl group, which strengthens its hold on serotonin receptors while leaving most other receptor types unaffected.[3][10] Cardiovascular adverse effects across the NBOMe class — tachycardia, elevated blood pressure, overheating — likely involve serotonin receptor activation plus possible effects on epinephrine receptors.[11]inferred
Pharmacokinetics
No human pharmacokinetic studies have been published for 25N-NBOMe. NBOMe compounds are poorly absorbed when swallowed — stomach degradation and liver metabolism destroy much of the dose.[2] Sublingual administration bypasses this barrier; insufflation produces faster onset and higher peak concentrations, substantially raising overdose risk.[3]
Neuroscience[edit]
Where it acts
25N-NBOMe acts primarily on neurons in the prefrontal cortex — the brain region governing reasoning, perception, and sense of self.[1] Activating these cells increases glutamate release, disrupts the brain's default mode network, and weakens the filtering of sensory information reaching awareness. The result is heightened perceptual complexity: vivid visuals, altered thinking, and a loosened sense of self.
Frameworks and plasticity
NBOMe compounds notably lack activity at a serotonin receptor subtype that classical psychedelics like LSD stimulate.[10] That receptor is thought to buffer anxiety, and its absence may explain why NBOMe experiences are consistently reported as more anxious and less forgiving.
Laboratory studies show that NBOMe compounds damage energy-producing structures inside nerve cells.[12] Whether this translates to lasting harm at recreational doses in humans remains unknown.
No neuroimaging studies of 25N-NBOMe exist. Key unknowns include whether the compound promotes neuroplasticity, whether its unique nitro-group metabolites carry neurotoxic risk, and whether the absence of that anxiety-buffering receptor activity is the mechanistic driver of its anxiogenic profile.
Subjective Effects[edit]
25N-NBOMe delivers an experience defined by intense visual distortion, physical stimulation, and a persistent undercurrent of anxiety. The steep dose-response curve leaves little margin between an interesting trip and an overwhelming one — set and setting carry unusually high weight because the pharmacology offers little internal buffer against difficult emotions.
Compared to LSD, 25N-NBOMe shares similar serotonin-receptor potency but lacks the broader receptor activity that softens LSD's character. Relative to psilocybin, reports describe a more visually driven, more stimulating, and more anxiety-prone experience — though these comparisons rest on user reports rather than controlled studies.
The compound originated in Ralf Heim's 2003 doctoral research at the Free University of Berlin, where NBOMe compounds were designed as radioligands for brain imaging.[2] It appeared on research chemical markets around 2010, part of an NBOMe wave that produced over 50 severe intoxication cases and at least 9 fatalities across the series.[3][2] 25N-NBOMe remains one of the least-distributed NBOMe analogs, controlled in most jurisdictions through blanket psychoactive substance legislation rather than individual scheduling.
Subjective effects include geometric visual patterns, time alteration, stimulation, and anxiety. The experience is marked by a steep intensity curve and a pronounced anxiogenic edge — an unforgiving compound where small dose adjustments dramatically shift the character of the trip. Thought loops, paranoia, and overwhelming sensory intensity are common unsought effects.
25N-NBOMe produces no physical dependence, but the NBOMe class carries severe acute toxicity — seizures, organ failure, and cardiovascular collapse have caused multiple fatalities.[4] The dose-response curve is exceptionally steep, compressing the margin between a manageable experience and a medical emergency into an unpredictable sliver. No clinical studies have been conducted on 25N-NBOMe; the current understanding rests on class-level pharmacology, in vitro data, and community reports.
History[edit]
Discovery
The structural ancestor of 25N-NBOMe is 2C-N, a 4-nitro-substituted phenethylamine synthesized and self-tested by Alexander Shulgin, who documented the compound in PiHKAL (1991).[5] 2C-N was active at 100–150 mg — orders of magnitude above the microgram potency of the NBOMe derivative that would follow. The critical advance came from Ralf Heim, whose 2003 doctoral thesis at the Free University of Berlin described the addition of an N-(2-methoxybenzyl) group to 2C-series compounds, producing dramatically enhanced 5-HT₂A receptor affinity for use as potential PET brain-imaging radioligands.[2]
Designer drug emergence
The NBOMe series appeared on online research chemical markets around 2010.[2] 25I-NBOMe, 25B-NBOMe, and 25C-NBOMe dominated distribution; 25N-NBOMe circulated in smaller volumes. The compounds were routinely sold on blotter paper and misrepresented as LSD, a substitution made possible by their microgram-level dosing. Reports of severe intoxication and death accumulated rapidly, with more than 50 confirmed acute toxicity cases and at least 9 fatalities across the series.[3][2]
Prohibition
Regulatory responses came in waves: Russia controlled the series in 2011, Sweden in 2013, and the United States permanently placed 25I-, 25C-, and 25B-NBOMe in Schedule I in October 2016.[6] 25N-NBOMe was not individually named in the US action but is likely covered by the Federal Analogue Act. Brazil explicitly listed 25N-NBOMe in 2014, and the UK's Psychoactive Substances Act 2016 provides blanket coverage.[7]
The name "NBOMe" derives from the compound's defining structural feature: the N-2-methoxybenzyl group appended to the phenethylamine nitrogen. Within drug culture, NBOMe compounds are sometimes called "N-bombs" — a phonetic shortening that acquired darker connotations as fatality reports accumulated. The series carries a distinctly negative reputation among psychedelic users: the combination of steep dose-response curves, misrepresentation as LSD, and documented deaths made "NBOMe" shorthand for the risks of unregulated psychedelic markets.
Chemistry[edit]
Structural class
25N-NBOMe belongs to the 25X-NBOMe series of substituted phenethylamines. The class shares a common architecture: a phenethylamine backbone with methoxy groups at the 2- and 5-positions, a variable substituent at position 4, and an N-(2-methoxybenzyl) extension — the "NBOMe" moiety — that converts low-potency 2C-series compounds into high-potency serotonin 2A receptor agonists.[3] The parent compound is 2C-N.[5]
The 4-nitro substituent (–NO₂) is unique within the NBOMe series. Other members carry halogens, methyl, or ethyl groups at this position. The electron-withdrawing nitro group gives 25N-NBOMe distinctive metabolic behavior — notably, susceptibility to enzymatic reduction to a primary aromatic amine.[8]
Molecular identity
| Molecular formula | C₁₈H₂₂N₂O₅ |
| Molecular weight | 346.4 g/mol |
The molecule consists of two aromatic rings linked by an ethylamine chain. The phenethylamine ring carries methoxy groups at positions 2 and 5 and the nitro group at position 4. The N-benzyl ring bears a methoxy group at its 2-position, forming the NBOMe pharmacophore.
Stereochemistry
25N-NBOMe contains no chirality centers and exists as a single achiral species.
Pharmacology[edit]
Mechanism of action
25N-NBOMe produces its psychedelic effects through full agonism at serotonin 5-HT₂A receptors.[3] Unlike the parent 2C compounds, which act as partial agonists, NBOMe compounds activate the receptor with full efficacy — producing more intense downstream signaling at equivalent receptor occupancy.[1]
The N-2-methoxybenzyl group is the structural feature responsible for this potency increase. Its addition to the 2C-N scaffold dramatically strengthens binding at 5-HT₂A while maintaining strong selectivity — the compound has negligible activity at 5-HT₁A receptors.[3][9] In animal models, the behavioral effects of NBOMe compounds are completely blocked by the selective 5-HT₂A antagonist M100907, confirming that this single receptor is both necessary and sufficient for the acute psychedelic response.[10]
The cardiovascular adverse effects seen across the NBOMe class — tachycardia, elevated blood pressure, overheating — likely involve both 5-HT₂A-mediated autonomic activation and possible direct activity at epinephrine receptors.[11] No study has measured 25N-NBOMe's binding at adrenergic receptors specifically; this remains a class-level inference.inferred
Pharmacokinetics
No human pharmacokinetic studies of 25N-NBOMe have been published. Absorption, distribution, metabolism, and elimination parameters remain entirely uncharacterized in humans.
NBOMe compounds are poorly absorbed when swallowed, likely due to stomach degradation and extensive first-pass liver metabolism.[2] Sublingual or buccal administration bypasses this barrier and is the primary active route. Insufflation produces faster onset and higher peak concentrations, substantially increasing overdose risk.[3]
Onset following sublingual administration is reported at 45–75 minutes, with peak effects at 2–3 hours and total duration of 5–10 hours.safety citation needed These values derive from community estimates and have not been confirmed by clinical measurement for 25N-NBOMe specifically.
Neuroscience[edit]
Where it acts
As a potent serotonin 2A receptor agonist,[1] 25N-NBOMe is expected to act primarily on layer V pyramidal neurons in the prefrontal cortex — the same population targeted by classical psychedelics. Activation here increases glutamate release, disrupts the brain's default mode network, and weakens the thalamus's filtering of sensory input to cortical areas. The result is heightened perceptual complexity and reduced top-down cognitive control, experienced as visual distortion, altered thinking, and loosened sense of self.
The absence of meaningful 5-HT₁A activity in NBOMe compounds[9] may be clinically significant: 5-HT₁A agonism is thought to contribute anxiety-buffering effects in substances like LSD, and its absence could explain the pronounced anxiogenic character reported for NBOMe experiences.
Frameworks and plasticity
The REBUS model (Relaxed Beliefs Under Psychedelics) proposes that psychedelics loosen the brain's established predictions, allowing sensory input to override entrenched patterns of thought. 25N-NBOMe's full 5-HT₂A agonism and steep dose-response relationship suggest potent disruption of top-down processing, consistent with the reality-testing impairment reported at higher doses.
Serotonergic psychedelics are also under investigation as psychoplastogens — compounds that promote structural brain connectivity. Whether 25N-NBOMe shares this property is unknown. In vitro data show that NBOMe compounds cause mitochondrial damage and energy depletion in neuronal cells,[12] raising the question of whether any plasticity-promoting effects are offset by neurotoxic potential.
No neuroimaging studies of 25N-NBOMe exist. Key unknowns include whether the compound promotes neuroplasticity at doses below its toxic threshold, whether its unique nitro-group metabolites carry neurotoxic risk, and whether the absence of 5-HT₁A activity is the mechanistic driver of its anxiogenic profile. Comparative imaging studies against LSD or psilocybin could clarify these questions but have not been conducted.
Subjective Effects[edit]
25N-NBOMe delivers an experience defined by visual intensity, physical stimulation, and an anxiogenic undercurrent that users consistently describe as harsher than classical psychedelics. The steep dose-response curve compresses the range between a manageable trip and an overwhelming one into a narrow band — small dose changes can shift the experience from lucid and visual to disorienting and frightening. Set and setting exert particularly strong influence: the compound's lack of 5-HT₁A modulation leaves little pharmacological buffer against anxiety, placing more weight on psychological preparation and environment.
Compared to LSD, 25N-NBOMe shares comparable potency at 5-HT₂A but lacks the broader receptor activity that shapes LSD's character. Relative to psilocybin, the experience is reported as more visually driven, more physically stimulating, and qualitatively more anxiety-prone — though these comparisons rest entirely on uncontrolled user reports, not head-to-head studies.
Effect Grid
Full psychedelic effects manifest — prominent color enhancement, visual drifting, geometric patterning, and object transformations. Internal hallucinations become possible. Emotional enhancement intensifies, and time alteration is pronounced. Thought connectivity and conceptual thinking deepen.
Physical load increases: stimulation is prominent, muscle tension and vasoconstriction may cause discomfort, nausea is common, and abnormal heartbeat becomes apparent. Wakefulness and appetite suppression are reliable. Anxiety can become a significant feature of the experience.
The steep dose-response means the upper range of this tier approaches strong-level intensity. Precise dosing and a supportive setting are strongly advised.
Modeled from the effect's dose-dependence curve — not per-substance measurements.
Visual breathing · Music enhancement · Symmetrical texture repetition · After-images · Brightness alteration · Color alteration · Tracers · Visual morphing · Auditory distortion · Auditory enhancement · Depth perception distortion · Light sensitivity · Peripheral vision distortion · Perspective distortion · Spatial disorientation · Visual haze / noise · Visual melting · Touch enhancement · Visual acuity enhancement · Auditory misinterpretation · Holotropic state · Peripheral misidentification · Proprioceptive distortion · Sound sensitivity · Vestibular distortion · Visual diffraction · Taste enhancement · Visual processing acceleration · Synesthesia · Visual magnification · Touch suppression · Flashbacks · Object transformations · Internal hallucinations · Visual recursion · Environmental orbism / cubism · External hallucinations · Object activation · Visual scenery slicing · Auditory hallucinations · Perspective hallucinations · Visual flipping · Gustatory hallucination · Persisting hallucinations
Brightness alteration · Color alteration · Tracers · Visual morphing · Auditory distortion · Auditory enhancement · Depth perception distortion · Light sensitivity · Peripheral vision distortion · Perspective distortion · Spatial disorientation · Visual haze / noise · Visual melting · Touch enhancement · Visual acuity enhancement · Auditory misinterpretation · Holotropic state · Peripheral misidentification · Proprioceptive distortion · Sound sensitivity · Vestibular distortion · Visual diffraction · Taste enhancement · Visual processing acceleration · Synesthesia · Visual magnification · Touch suppression · Flashbacks · Object transformations · Internal hallucinations · Visual recursion · Environmental orbism / cubism · External hallucinations · Object activation · Visual scenery slicing · Auditory hallucinations · Perspective hallucinations · Visual flipping · Gustatory hallucination · Persisting hallucinations
Spontaneous body sensations · Muscle tension · Nausea · Appetite suppression · Dry mouth · Body high · Heart rate perception changes · Restlessness · Excessive sweating · Insomnia · Physical fatigue · Tingling / electric sensations · Bodily lightness · Dehydration sensation · Headache · Body schema distortion · Breathing alteration · Dizziness · Laughter fits · Nystagmus (eye wobbles) · Salivation · Tactile euphoria · Trembling · Vibrations / buzzing · Bodily pressures · Bruxism · Involuntary body movements · Respiratory stimulation · Increased urination · Sexual arousal enhancement · Vomiting · Nasal congestion · Seizure threshold reduction · Bodily dissociation · Tactile hallucination
Appetite suppression · Dry mouth · Body high · Heart rate perception changes · Restlessness · Excessive sweating · Insomnia · Physical fatigue · Tingling / electric sensations · Bodily lightness · Dehydration sensation · Headache · Body schema distortion · Breathing alteration · Dizziness · Laughter fits · Nystagmus (eye wobbles) · Salivation · Tactile euphoria · Trembling · Vibrations / buzzing · Bodily pressures · Bruxism · Involuntary body movements · Respiratory stimulation · Increased urination · Sexual arousal enhancement · Vomiting · Nasal congestion · Bodily dissociation · Tactile hallucination
Thought acceleration · Immersion enhancement · Conceptual thinking · Cognitive euphoria · Cognitive flexibility · Cognitive impairment · Introspection enhancement · Multiple thought streams · Openness enhancement · Thought connectivity · Thought loops · Memory suppression · Cognitive fatigue · Confusion · Creativity enhancement · Focus suppression · Information processing suppression · Memory fragmentation · Thought disorganization · Increased nature relatedness · Humor enhancement · Analysis enhancement · Analysis suppression · Cognitive dysphoria · Language suppression · Synchronicity · Delusions · Amnesia · Delirium
Cognitive euphoria · Cognitive flexibility · Cognitive impairment · Introspection enhancement · Multiple thought streams · Openness enhancement · Thought connectivity · Thought loops · Memory suppression · Cognitive fatigue · Confusion · Creativity enhancement · Focus suppression · Information processing suppression · Memory fragmentation · Thought disorganization · Increased nature relatedness · Humor enhancement · Analysis enhancement · Analysis suppression · Cognitive dysphoria · Language suppression · Synchronicity · Amnesia · Delirium
Simultaneous emotions · Empathy enhancement · Catharsis · Dysphoria · Irritability
Irritability
Communication suppression · Social disconnection · Boundary dissolution · Cognitive disconnection · Ego dissolution · Identity alteration · Telepathic feelings
Ego dissolution · Identity alteration · Telepathic feelings
Time cessation
Transpersonal feelings · Non-dual awareness
Timeline
Gradual emergence of body awareness and sublingual numbing characteristic of the NBOMe class. Mild stimulation and slight pupil dilation begin.
Rapid escalation of visual and somatic effects. Color enhancement and surface texturing become apparent. Anxiety may intensify during this phase.
Full expression of visual, cognitive, and emotional effects. Maximum sympathomimetic load — tachycardia, muscle tension, and stimulation are most pronounced.
Gradual reduction in visual intensity; stimulation persists. Residual anxiety and muscle tension are common. Cognitive effects slowly clear.
Residual stimulation, possible insomnia, mild cognitive fatigue, and physical recovery. Mood may be flat or mildly dysphoric.
⚠ Do not drive or operate heavy machinery for at least 16 hours after sublingual administration — residual stimulation and cognitive impairment may persist beyond subjective resolution of primary effects.
Safety[edit]
- Acute toxicity
- Moderate
- Chronic toxicity
- Moderate
- Withdrawal
- None
- Tolerance buildup
- rapid
- Tolerance reset
- 7 days
- Physical
- None
- Psychological
- Negligible
- Compulsive redosing
- Low
- Dose escalation
- Negligible
- Cross-tol.
- LSD · psilo · mesc
Toxicity
Acute toxicity
The NBOMe class has caused over 50 severe intoxication cases and at least 9 deaths.[3][2] Severe intoxication presents with violent agitation, seizures, dangerously high body temperature, rapid heart rate, muscle breakdown, and kidney failure — progressing in the worst cases to multi-organ failure and coma.[4][13]
No lethal dose has been established for any species. The dose-response curve is steep: small increases produce disproportionate escalation in both desired and dangerous effects. Dose ranges from community consensus — threshold ~100 µg, light 100–300 µg, common 300–800 µg, strong 800–1,300 µg (sublingual) — have not been verified clinically.safety citation needed
Cardiovascular toxicity
Related NBOMe compounds prolong the heart's electrical recovery interval in rat studies — a disruption that can trigger fatal arrhythmias.[2] Whether 25N-NBOMe shares this property is untested, but the shared pharmacology makes it plausible.
Neurotoxicity
Laboratory studies show NBOMe compounds are more toxic to brain cells than their 2C precursors.[12] Damage involves disrupted energy production and depleted antioxidant defenses in nerve cell models. Whether these findings translate to harm at recreational doses in humans is unknown.
Psychological risks
Acute psychological risks include severe anxiety, panic, paranoia, confusion, and violent agitation.[4][13] The steep dose-response curve increases the chance of overwhelming experiences at doses only slightly above the intended range.
Persistent visual disturbances after use — a condition called HPPD (HPPD) — are a recognized class-level risk.[14] Psychosis is a risk for those with predisposing conditions. No prevalence data specific to 25N-NBOMe exist for either.
Tolerance and dependence
Tolerance develops rapidly after a single dose — serotonin receptors temporarily downregulate after activation. Community sources report near-complete tolerance immediately after use, recovering over roughly 7 days.safety citation needed
Cross-tolerance extends to LSD, psilocybin, mescaline, and 2C compounds via the shared serotonin receptor mechanism. No physical dependence or withdrawal has been reported.
Drug Interactions
No interaction studies specific to 25N-NBOMe have been published. The following are based on the compound's pharmacological profile.
Serotonergic agents (MAOIs, SSRIs, SNRIs, tramadol): Combining 25N-NBOMe with other serotonin-raising drugs can trigger serotonin syndrome — a potentially fatal state involving unstable heart rate, blood pressure, temperature, and mental state.[15] This combination is documented in the NBOMe class.
Tramadol carries dual risk: serotonin syndrome hazard plus seizure threshold-lowering, compounding the NBOMe class's intrinsic seizure risk.
Stimulants (cocaine, amphetamines): Combined increases in heart rate, blood pressure, and body temperature produce additive cardiovascular strain — raising the risk of heart rhythm disturbance, seizure, and cardiovascular crisis.
CYP2C9/CYP2C19 inhibitors (fluconazole, fluvoxamine, omeprazole): Based on metabolism data from 25I-NBOMe,[16] these medications could slow 25N-NBOMe clearance, increasing exposure and toxicity risk.
Contraindications
10 knownNo substance-specific contraindication data exist for 25N-NBOMe. The following are class-level contraindications based on the pharmacology of potent serotonin-activating compounds with cardiovascular stimulant effects.
Heart conditions — High blood pressure, irregular rhythm, and prior cardiac events. NBOMe compounds strain the cardiovascular system and may disrupt heart electrical intervals, creating risk of acute failure.
Seizure disorders — Seizures are documented across multiple NBOMe intoxication cases.[4][13] Pre-existing seizure disorders substantially increase this risk.
Psychiatric conditions — Psychotic spectrum disorders, bipolar disorder, and conditions involving impaired reality testing. Potent serotonin receptor activation can trigger psychosis and psychiatric crisis.
Concurrent serotonergic medication — MAOIs, SSRIs, SNRIs, and tramadol are contraindicated due to serotonin syndrome risk.[15]
Concurrent stimulant use — Cocaine, amphetamines, and other stimulants produce additive cardiovascular strain.
Harm Reduction[edit]
Forms & Identification
25N-NBOMe is almost always distributed on blotter paper — the same format as LSD. Reagent testing is essential: the Ehrlich reagent reacts with LSD but not with phenethylamines, providing a critical first-pass distinction. Reagent testing alone cannot identify 25N-NBOMe specifically among NBOMe analogs.
Powder forms carry additional hazard: the microgram-active dose range means small measurement errors can produce dangerous overdoses. Volumetric dosing from a known-concentration solution is the only reliable approach for powder.
Guidelines
- Test all material with reagent kits before use to distinguish NBOMe compounds from LSD
- Start with the lowest reported threshold dose (~100 µg sublingual) and do not redose
- Use only sublingual administration — insufflation dramatically increases overdose risk[3]
- Ensure a sober, trusted sitter is present throughout the experience
- Choose a safe, comfortable, familiar environment with access to water and temperature control
- Avoid physical exertion, which compounds cardiovascular strain
- Allow a minimum of 7 days between uses for tolerance to reset
- Avoid use with pre-existing heart conditions, seizure disorders, or psychiatric conditions
Set & Setting
25N-NBOMe's pronounced anxiety-inducing character makes psychological preparation and environment unusually important. Unlike LSD, NBOMe compounds lack the receptor activity thought to buffer anxiety — the pharmacology provides little internal cushion against difficult experiences.
A calm, familiar environment with a trusted, sober companion reduces the probability of anxiety escalating. The steep dose-response curve means an overwhelming experience cannot easily be modulated once underway.
Aftercare & integration. The anxiogenic quality of 25N-NBOMe means difficult experiences are common even at moderate doses. After acute effects subside, allow 24–48 hours of low-demand rest. Sleep disruption is typical; avoid stimulants and screens in the hours following offset.
If the experience was distressing, journaling within the first few days can help process difficult material. Persistent anxiety, visual disturbances, or intrusive thoughts lasting beyond one week should prompt consultation with a mental health professional.
Recovery & Support
Compulsive use patterns are rare with serotonergic psychedelics due to rapid tolerance buildup. If repeated use is causing distress or escalating risk-taking, professional support is warranted. Psychedelic-informed therapists, peer support communities, and services like the Fireside Project (62-FIRESIDE / 623-473-7433) offer non-judgmental assistance for people processing difficult psychedelic experiences or seeking to change their relationship with use.
Recovery resources, crisis lines, and support pathways → View all
Emergency Response
Recognizing an emergency:
- Seizures or uncontrollable muscle jerking
- Body temperature hot to the touch through clothing
- Chest pain or irregular heartbeat
- Complete loss of contact with reality, self-harm behavior, or violent agitation
- Loss of consciousness or unresponsiveness
- Dark or absent urine (sign of muscle breakdown and kidney damage)
Immediate steps:
- 1. Call emergency services immediately if any of the above are present
- 2. Move the person to a cool, quiet space
- 3. If conscious, offer small sips of water
- 4. If unconscious and breathing, place in the recovery position (on their side)
- 5. Do not restrain unless there is immediate danger of self-harm or harm to others
- 6. Do not induce vomiting
- 7. Monitor breathing continuously until help arrives
What to tell the dispatcher: Name the substance (25N-NBOMe or "an NBOMe compound"), estimated amount taken, time of ingestion, and current symptoms. Good Samaritan laws in many jurisdictions protect callers who report drug emergencies from prosecution.
Legal Status[edit]
25N-NBOMe is individually named in only a few national frameworks. In most countries, blanket psychoactive substance legislation or structural analog provisions apply because the three most-distributed analogs — 25I-NBOMe, 25C-NBOMe, and 25B-NBOMe — are explicitly controlled.
| Jurisdiction | Classification | Key provisions |
|---|---|---|
| United States | Not individually scheduled (Federal Analogue Act applies) | 25I-, 25C-, and 25B-NBOMe permanently placed in Schedule I (October 2016).[6] 25N-NBOMe not individually named but likely covered under the Federal Analogue Act when intended for human consumption. |
| United Kingdom | Controlled (Psychoactive Substances Act 2016) | Blanket prohibition on production, supply, and import of psychoactive substances. 25I-NBOMe and 25C-NBOMe additionally designated Class A (2014).[7] |
| Brazil | Controlled | 25N-NBOMe explicitly listed as a controlled substance (February 2014).[7] |
| Canada | Schedule III | Covered under "2C-phenethylamines and their salts, derivatives, isomers" since October 2016.[7] |
| Russia | Controlled | NBOMe series controlled since October 2011.[7] |
| Sweden | Controlled | Added to controlled substances list August 2013.[7] |
| Australia | Schedule 9 (varies by state) | 25I-NBOMe is nationally prohibited; state-level schedules vary for other analogs. |
Legal status changes frequently and varies by jurisdiction. This information is not legal advice. Verify current status in the applicable jurisdiction before making any decisions.
Safety[edit]
- Acute toxicity
- Moderate
- Chronic toxicity
- Moderate
- Withdrawal
- None
- Tolerance buildup
- rapid
- Tolerance reset
- 7 days
- Physical
- None
- Psychological
- Negligible
- Compulsive redosing
- Low
- Dose escalation
- Negligible
- Cross-tol.
- LSD · psilo · mesc
Toxicity
Acute toxicity
The NBOMe class has a documented history of severe acute harm. More than 50 cases of severe intoxication and at least 9 deaths have been recorded across the series.[3][2] No published fatality has been attributed specifically to 25N-NBOMe, but its pharmacological profile — full 5-HT₂A agonism with sympathomimetic activity — supports a comparable risk classification.
Severe NBOMe intoxication typically presents with violent agitation, seizures, dangerously high body temperature, rapid heart rate, high blood pressure, muscle breakdown, kidney failure, and in the worst cases, multi-organ failure and coma.[4][13]
No lethal dose has been established in any species. The dose-response curve is notoriously steep: small dose increases produce disproportionate escalation in both desired and toxic effects.
Dose ranges (sublingual) from community consensus — threshold ~100 µg, light 100–300 µg, common 300–800 µg, strong 800–1,300 µg — have not been verified by any clinical study.safety citation needed
Cardiovascular toxicity
Related NBOMe compounds (25D-NBOMe and 25C-NBOMe) prolong QT intervals in rat heart studies.[2] Whether 25N-NBOMe shares this property has not been tested, but the risk is plausible given the shared pharmacology and the rapid heart rate and high blood pressure seen across the class.
Neurotoxicity
Laboratory studies show that NBOMe compounds are more toxic to brain cells than their 2C counterparts.[12] Damage mechanisms include mitochondrial disruption, energy depletion, and antioxidant exhaustion in neuronal cell models. Whether these findings translate to brain damage at doses used recreationally in humans is unknown.
Psychological risks
Acute psychological adverse effects across the NBOMe class include severe anxiety, panic, paranoia, confusion, violent agitation, and excited delirium.[4][13] The steep dose-response relationship increases the likelihood of overwhelming experiences at doses only slightly above the intended range.
Hallucinogen persisting perception disorder (HPPD) — persistent visual disturbances after psychedelic use — is a recognized class-level risk.[14] No HPPD cases specifically attributed to 25N-NBOMe have been published.
Psychosis and psychiatric destabilization are recognized risks of potent 5-HT₂A agonists, particularly in individuals with predisposing conditions. No prevalence data specific to 25N-NBOMe exist.
Tolerance and dependence
Tolerance develops rapidly after a single dose, consistent with 5-HT₂A downregulation — the standard mechanism across serotonergic psychedelics. Community sources report near-complete tolerance immediately after use, with a half-life of approximately 3 days and full reset within 7 days.safety citation needed These values are plausible but unconfirmed for 25N-NBOMe specifically.
Cross-tolerance extends to other serotonergic psychedelics (LSD, psilocybin, mescaline, 2C compounds) via the shared 5-HT₂A mechanism.
No abuse liability has been documented. No animal self-administration studies exist. Physical dependence and withdrawal have not been reported. The 5-HT₂A agonist mechanism is associated with very low dependence potential across the psychedelic class.
Drug Interactions
No interaction studies specific to 25N-NBOMe have been published. The following assessments are based on the compound's pharmacological profile.
Serotonergic agents (MAOIs, SSRIs, SNRIs, tramadol): 25N-NBOMe is a potent 5-HT₂A full agonist. Co-administration with other serotonergic compounds raises the risk of serotonin syndrome — a potentially fatal condition involving dangerously unstable heart rate, blood pressure, temperature, and mental state. Serotonin syndrome has been documented for NBOMe compounds.[15]
Tramadol poses dual risk: serotonergic activity compounds the serotonin syndrome hazard, and its seizure threshold-lowering properties amplify the intrinsic seizure risk of the NBOMe class.
Stimulants (cocaine, amphetamines): Additive cardiovascular strain — combined rapid heart rate, high blood pressure, overheating, and vasoconstriction risk heart rhythm disturbances, seizures, and cardiovascular crisis.
CYP2C9/CYP2C19 inhibitors (fluconazole, fluvoxamine, omeprazole): Based on metabolism data from 25I-NBOMe,[16] these medications could slow 25N-NBOMe clearance, increasing exposure and toxicity risk.
Contraindications
10 knownNo substance-specific contraindication data exist for 25N-NBOMe. The following are class-level contraindications based on the pharmacology of potent 5-HT₂A agonists with sympathomimetic activity:
Heart conditions — High blood pressure, irregular heart rhythm, and prior cardiac events. The cardiovascular strain and possible QT prolongation produced by NBOMe compounds create risk of acute cardiovascular failure.
Seizure disorders — Seizures are documented in multiple NBOMe intoxication cases.[4][13] Pre-existing seizure disorders substantially increase this risk.
Psychiatric conditions — Psychotic spectrum disorders, bipolar disorder, and conditions involving impaired reality testing are contraindicated due to the risk of psychosis and psychiatric crisis from potent 5-HT₂A agonism.
Concurrent serotonergic medication — MAOIs, SSRIs, SNRIs, tramadol, and other serotonergic agents are contraindicated due to serotonin syndrome risk.[15]
Concurrent stimulant use — Cocaine, amphetamines, and other sympathomimetic agents produce additive cardiovascular strain.
Harm Reduction[edit]
Forms & Identification
The structured data module above shows reagent results and physical form data. For 25N-NBOMe, testing is essential because the compound is routinely distributed on blotter paper — the same format as LSD — and deliberate misrepresentation as LSD has been widely documented. A reagent test that reacts to NBOMe compounds but not to LSD (such as the Ehrlich reagent, which produces no color change with phenethylamines) provides a critical first-pass distinction. Reagent testing alone cannot confirm 25N-NBOMe specifically versus other NBOMe analogs.
Powder forms carry additional risk: the microgram-active dose range means that even small measurement errors can produce dangerous overdoses. Volumetric dosing from a known-concentration solution is the only reliable approach for powder.
Guidelines
- Test all material with reagent kits before use to distinguish NBOMe compounds from LSD
- Start with the lowest reported threshold dose (~100 µg sublingual) and do not redose
- Use only sublingual administration — insufflation dramatically increases overdose risk[3]
- Ensure a sober, trusted sitter is present throughout the experience
- Choose a safe, comfortable, familiar environment with access to water and temperature control
- Avoid physical exertion, which compounds cardiovascular strain
- Allow a minimum of 7 days between uses for tolerance to reset
- Do not use if you have a heart condition, seizure disorder, or psychiatric condition
Set & Setting
25N-NBOMe's pronounced anxiogenic character makes psychological preparation and environment unusually important. The compound lacks the 5-HT₁A receptor activity thought to buffer anxiety in substances like LSD — the pharmacology offers little internal cushion against difficult experiences.
A calm, familiar environment with minimal external stressors and a trusted, sober companion reduces the probability of anxiety escalation. First-time users and those with any history of anxiety should approach with particular caution. The steep dose-response curve means that an overly intense experience cannot easily be modulated once underway.
Aftercare & integration. The anxiogenic quality of 25N-NBOMe means that difficult or frightening experiences are common even at moderate doses. After the acute effects subside, allow 24–48 hours of low-demand rest. Sleep disruption is typical; avoid stimulants and screens in the hours following offset.
If the experience was distressing, journaling within the first few days can help process difficult material. Talking with a trusted friend or an integration-trained therapist is particularly valuable after overwhelming or frightening trips. Persistent anxiety, visual disturbances, or intrusive thoughts lasting beyond one week should prompt consultation with a mental health professional.
Recovery & Support
Compulsive use patterns are rare with serotonergic psychedelics due to rapid tolerance buildup. If repeated use is causing distress, social impairment, or escalating risk-taking, professional support is warranted. Psychedelic-informed therapists, peer support communities, and services like the Fireside Project (62-FIRESIDE / 623-473-7433) offer non-judgmental assistance for people processing difficult psychedelic experiences or seeking to change their relationship with use.
Recovery resources, crisis lines, and support pathways → View all
Emergency Response
Recognizing an emergency:
- Seizures or uncontrollable muscle jerking
- Body temperature hot to the touch through clothing
- Chest pain or irregular heartbeat
- Complete loss of contact with reality, self-harm behavior, or violent agitation
- Loss of consciousness or unresponsiveness
- Dark or absent urine (sign of muscle breakdown and kidney damage)
Immediate steps:
- 1. Call emergency services immediately if any of the above are present
- 2. Move the person to a cool, quiet space
- 3. If conscious, offer small sips of water
- 4. If unconscious and breathing, place in the recovery position (on their side)
- 5. Do not restrain unless there is immediate danger of self-harm or harm to others
- 6. Do not induce vomiting
- 7. Monitor breathing continuously until help arrives
What to tell the dispatcher: Name the substance (25N-NBOMe or "an NBOMe compound"), estimated amount taken, time of ingestion, and current symptoms. Good Samaritan laws in many jurisdictions protect callers who report drug emergencies from prosecution.
Legal Status[edit]
25N-NBOMe occupies a fragmented regulatory landscape. While the three most prevalent NBOMe analogs (25I-NBOMe, 25C-NBOMe, and 25B-NBOMe) have been explicitly scheduled in most major jurisdictions, 25N-NBOMe is individually named in only a few national frameworks. In practice, blanket psychoactive substance legislation and structural analog provisions cover 25N-NBOMe in most countries where the parent analogs are controlled.
| Jurisdiction | Classification | Key provisions |
|---|---|---|
| United States | Not individually scheduled (Federal Analogue Act applies) | 25I-, 25C-, and 25B-NBOMe permanently placed in Schedule I (October 2016).[6] 25N-NBOMe not individually named but likely covered under the Federal Analogue Act when intended for human consumption. |
| United Kingdom | Controlled (Psychoactive Substances Act 2016) | Blanket prohibition on production, supply, and import of psychoactive substances. 25I-NBOMe and 25C-NBOMe additionally designated Class A (2014).[7] |
| Brazil | Controlled | 25N-NBOMe explicitly listed as a controlled substance (February 2014).[7] |
| Canada | Schedule III | Covered under "2C-phenethylamines and their salts, derivatives, isomers" since October 2016.[7] |
| Russia | Controlled | NBOMe series controlled since October 2011.[7] |
| Sweden | Controlled | Added to controlled substances list August 2013.[7] |
| Australia | Schedule 9 (varies by state) | 25I-NBOMe is nationally prohibited; state-level schedules vary for other analogs. |
The Federal Analogue Act (21 U.S.C. § 813) extends Schedule I or II controls to substances "substantially similar" in chemical structure or pharmacological effect to a listed substance, when intended for human consumption. Given 25N-NBOMe's structural and pharmacological similarity to the three permanently scheduled NBOMe compounds, prosecution under this provision is legally viable in the United States.
Frequently asked questions
What is 25N-NBOMe?
25N-NBOMe is a synthetic psychedelic phenethylamine of the 25x-NBOMe series, active at microgram doses via sublingual administration. It acts as a full-efficacy 5-HT₂A receptor agonist, derived from 2C-N via N-(2-methoxybenzyl) substitution.
How long does 25N-NBOMe last?
Total duration by route of administration — Sublingual: 5 – 10 hours. Ranges vary with dose and individual factors; see the duration table for onset, peak, and after-effect phases.
Where can I find dosage information for 25N-NBOMe?
Psychedex publishes a dosage table for 25N-NBOMe on this page covering these routes of administration: sublingual. Dose values are presented only in that table, always alongside their route of administration.
What are dangerous combinations with 25N-NBOMe?
The highest-severity documented interactions for 25N-NBOMe: MAOIs (Lethal), Buspirone (Dangerous), Dopamine agonists (Dangerous), GHB, Baclofen (Dangerous), GHB, GBL (Dangerous). See the interactions section for the full list with mechanisms and severity levels.
Is 25N-NBOMe addictive?
Psychedex records tolerance and dependence data rather than a yes/no rating. Recorded tolerance indicators for 25N-NBOMe: tolerance builds rapid; full reset takes 7 days; cross-tolerance develops with LSD, psilocybin, mescaline, 2C-x compounds, other NBOMe compounds. See the article's dependence and safety sections for recorded dependence data.
experience reports
No experience reports yet. Be the first to contribute.
First-person accounts of subjective effects, timing, and outcomes — submitted for harm reduction.
references
- [1] ^abcEshleman AJ, Wolfrum KM, Reed JF, Kim SO, Johnson RA, Janowsky A (2018) Neurochemical pharmacology of psychoactive substituted N-benzylphenethylamines: High potency agonists at 5-HT2A receptors. — Biochemical Pharmacology doi:10.1016/j.bcp.2018.09.024
- [2]
- [3]
- [4] ^abcdGee P, Schep LJ, Jensen BP, Moore G, Barrington S (2016) Case series: toxicity from 25B-NBOMe--a cluster of N-bomb cases. — Clinical Toxicology doi:10.3109/15563650.2015.1115056
- [5]
- [6]
references
- [1] ^abcEshleman AJ, Wolfrum KM, Reed JF, Kim SO, Johnson RA, Janowsky A (2018) Neurochemical pharmacology of psychoactive substituted N-benzylphenethylamines: High potency agonists at 5-HT2A receptors. — Biochemical Pharmacology doi:10.1016/j.bcp.2018.09.024
- [2]
- [3]
- [4] ^abcdGee P, Schep LJ, Jensen BP, Moore G, Barrington S (2016) Case series: toxicity from 25B-NBOMe--a cluster of N-bomb cases. — Clinical Toxicology doi:10.3109/15563650.2015.1115056
- [5]
- [6]